# Breast Cancer Screening and Diagnostic Workup

## Epidemiology

Breast cancer is the most common cancer in women worldwide and the second leading cause of cancer death in women. The lifetime risk is approximately 1 in 8 (12.5%) for average-risk women. Incidence increases with age, with a median age at diagnosis of approximately 62 years. Male breast cancer accounts for less than 1% of all breast cancers.

## Risk Assessment

### Risk Factors

Non-modifiable risk factors include female sex, increasing age, family history (particularly in first-degree relatives), BRCA1/2 mutations, prior chest radiation between ages 10 and 30, personal history of breast cancer, atypical ductal hyperplasia, and lobular carcinoma in situ. Modifiable risk factors include postmenopausal obesity, alcohol consumption, combined hormone replacement therapy (estrogen-progesterone), physical inactivity, nulliparity, and late first pregnancy (after age 30). Protective factors include breastfeeding, early first full-term pregnancy, physical activity, and prophylactic mastectomy or oophorectomy in BRCA carriers.

### Risk Models

The Gail model estimates 5-year and lifetime risk using age, race, age at menarche, age at first live birth, number of first-degree relatives, and prior biopsies. Its key limitation is that it does not account for paternal family history or second-degree relatives. The Tyrer-Cuzick (IBIS) model is more comprehensive, incorporating detailed family history, hormonal factors, BMI, and genetic information, and is preferred for comprehensive risk assessment. A lifetime risk exceeding 20% qualifies a patient as high risk and makes her eligible for enhanced screening with MRI.

### Genetic Testing

Genetic testing is indicated when there is a strong family history, young age at diagnosis, triple-negative breast cancer before age 60, male breast cancer, Ashkenazi Jewish heritage, or a known pathogenic variant in the family. Relevant genes include BRCA1 and BRCA2 (which carry the highest risk), along with PALB2, ATM, CHEK2, TP53, CDH1, PTEN, and STK11. Genetic counseling should be provided both before and after testing. BRCA1 mutations confer a 60-70% lifetime breast cancer risk, while BRCA2 mutations confer a 45-55% risk.

<image>Risk assessment flowchart showing patient stratification into average-risk, intermediate-risk, and high-risk categories with corresponding screening recommendations</image>

## Screening Guidelines

### Average-Risk Women

The USPSTF (2024) recommends biennial mammography for women ages 40-74. The ACS recommends annual mammography starting at age 45 (with the option to begin at 40-44), transitioning to biennial screening at age 55 and beyond. The ACR/SBI and NCCN recommend annual mammography starting at age 40. The consensus across all guidelines is that mammography is the only screening modality proven to reduce breast cancer mortality in average-risk women.

### High-Risk Women (>20% Lifetime Risk)

High-risk women should undergo annual mammography plus annual breast MRI starting at age 25-30, or 10 years before the youngest affected relative, whichever is later. This applies to BRCA1/2 carriers, those with Li-Fraumeni syndrome (TP53 mutations), prior chest radiation recipients, and carriers of other high-penetrance mutations. MRI has higher sensitivity than mammography, especially in dense breasts, but lower specificity.

### Intermediate-Risk Women (15-20% Lifetime Risk)

Guidelines vary for this group, and some recommend adding MRI to annual mammography. The decision should be individualized based on risk-benefit discussion with the patient.

### Dense Breasts

Mammographic breast density is both an independent risk factor for breast cancer and a factor that reduces mammographic sensitivity. Many states mandate patient notification of breast density. Supplemental screening options include breast ultrasound, MRI, and contrast-enhanced mammography, though there is no consensus on the optimal supplemental screening modality.

## Breast Imaging

### Mammography

Screening mammography is performed bilaterally with two views per breast (craniocaudal and mediolateral oblique) in asymptomatic patients. Diagnostic mammography provides targeted evaluation with additional views such as spot compression and magnification for symptomatic patients or abnormal screening findings. Digital breast tomosynthesis (DBT/3D mammography) improves cancer detection and reduces recall rates, especially in dense breasts, and is increasingly used as the standard approach. Overall mammographic sensitivity is 75-85%, though it is lower in dense breasts at 48-64%.

### BI-RADS Classification (Breast Imaging Reporting and Data System)

The BI-RADS system standardizes breast imaging reporting:

| BI-RADS | Assessment | Malignancy Risk | Management |
|---------|-----------|----------------|------------|
| 0 | Incomplete | — | Additional imaging |
| 1 | Negative | ~0% | Routine screening |
| 2 | Benign | ~0% | Routine screening |
| 3 | Probably benign | <2% | Short-interval follow-up (6 months) |
| 4A | Low suspicion | 2–10% | Biopsy |
| 4B | Moderate suspicion | 10–50% | Biopsy |
| 4C | High suspicion | 50–95% | Biopsy |
| 5 | Highly suggestive of malignancy | >95% | Biopsy |
| 6 | Known malignancy | 100% | Surgical planning |

BI-RADS 0 indicates an incomplete assessment requiring additional imaging. BI-RADS 1 is negative, and BI-RADS 2 denotes a benign finding; both call for routine screening. BI-RADS 3 indicates a probably benign finding with less than 2% malignancy risk and warrants short-interval follow-up at 6 months. BI-RADS 4 indicates a suspicious finding with 2-95% malignancy risk and is subdivided into 4A (low suspicion, 2-10%), 4B (moderate suspicion, 10-50%), and 4C (high suspicion, 50-95%); biopsy is recommended. BI-RADS 5 is highly suggestive of malignancy with greater than 95% risk, and biopsy is required. BI-RADS 6 denotes a known biopsy-proven malignancy.

### Breast Ultrasound

Breast ultrasound is used to evaluate palpable masses (especially in young patients or those with dense breasts), characterize mammographic abnormalities, guide biopsies, evaluate axillary lymph nodes, and provide supplemental screening in dense breasts. It distinguishes cystic from solid masses. A simple cyst -- anechoic, thin-walled, with posterior acoustic enhancement -- is benign and does not require biopsy. Solid masses are evaluated with BI-RADS criteria and biopsied if suspicious features are present. Ultrasound is operator-dependent, though automated breast ultrasound is an emerging option for screening.

### Breast MRI

Breast MRI is the most sensitive modality for breast cancer detection, with sensitivity exceeding 95%. Its indications include screening in high-risk patients (greater than 20% lifetime risk), extent of disease evaluation in newly diagnosed cancer (though its routine use remains controversial), evaluation of occult primary breast cancer when axillary nodes are positive but mammogram and ultrasound are negative, assessment of treatment response to neoadjuvant chemotherapy, screening of the contralateral breast in known cancer, and post-lumpectomy evaluation with positive margins. Limitations include lower specificity with resultant false positives, the need for intravenous contrast, expense, and claustrophobia.

### Contrast-Enhanced Mammography (CEM)

Contrast-enhanced mammography is a dual-energy technique using iodinated contrast that achieves sensitivity similar to MRI while being more accessible and less expensive. It has an emerging role in both screening and diagnostic workup and serves as an alternative for patients who cannot undergo MRI.

<image>BI-RADS classification examples showing representative mammographic images for categories 1 through 5 with corresponding management recommendations</image>

## Diagnostic Workup of Breast Lesions

### Palpable Mass

For patients under age 30, ultrasound is the first-line imaging study, as it avoids radiation and higher breast density makes mammography less useful. For patients over 30, both mammography and ultrasound should be obtained. A palpable mass with negative imaging still requires tissue sampling, as imaging has a false-negative rate and clinical concern should override negative imaging.

### Image-Guided Biopsy Techniques

#### Core Needle Biopsy (CNB)

Core needle biopsy is the preferred method for tissue diagnosis and has replaced excisional biopsy as the initial diagnostic step. It is performed using a spring-loaded or vacuum-assisted device. Ultrasound-guided CNB is the most common technique and provides real-time visualization for ultrasound-visible lesions. Stereotactic (mammogram-guided) CNB is used for calcifications or mammographic-only findings and requires either a prone table or upright attachment; vacuum-assisted devices (11-gauge or 8-gauge) are preferred for calcifications. MRI-guided CNB is reserved for lesions visible only on MRI. A tissue marker (clip) should be placed at the biopsy site for future localization, and specimen radiography should be performed for calcifications to confirm retrieval.

#### Fine Needle Aspiration (FNA)

Fine needle aspiration has a limited role in breast diagnosis because it cannot distinguish invasive from in situ disease. It may be used for cyst aspiration, axillary lymph node sampling, and confirmation of metastatic disease. It has a higher insufficient or non-diagnostic rate than core needle biopsy.

### Concordance Assessment

Concordance assessment is a critical step that ensures the pathology result is concordant with imaging findings. A discordant result, such as benign pathology for a BI-RADS 5 lesion, requires repeat biopsy or excision. Radiologic-pathologic correlation should be documented.

### Excisional Biopsy

Excisional biopsy is rarely used as an initial diagnostic procedure, having been replaced by core needle biopsy. Its indications include discordant CNB results, CNB showing an atypical lesion requiring excision, non-diagnostic CNB, and patient preference. Wire-localized or seed-localized excision is used for non-palpable lesions.

<image>Ultrasound-guided core needle biopsy technique showing the biopsy needle traversing the breast tissue and targeting a suspicious hypoechoic mass with real-time visualization</image>

## High-Risk Lesions Requiring Excision After CNB

Atypical ductal hyperplasia found on core needle biopsy upgrades to DCIS or cancer on excision in 15-30% of cases. Lobular carcinoma in situ should be excised if discordant with imaging or if pleomorphic LCIS is identified; classic LCIS may be observed with close follow-up if concordant. Atypical lobular hyperplasia is managed similarly to LCIS, with excision for concordance and upgrade assessment. Papillary lesions with atypia require excision. Radial scars should be excised if atypia is present, though observation may be appropriate for small, concordant radial scars without atypia. Flat epithelial atypia management is controversial; excision is recommended if associated with other atypia or discordance.

## Clinical Pearls

A palpable mass with negative imaging still needs tissue sampling because clinical concern overrides negative imaging. Core needle biopsy has replaced excisional biopsy as the initial tissue diagnosis method because it is less invasive, more cost-effective, and allows preoperative treatment planning. Radiologic-pathologic concordance must always be confirmed, and discordant results require re-biopsy or excision. BI-RADS 3 lesions should not be biopsied initially given the low malignancy risk but require short-interval follow-up at 6 months. Breast MRI is the most sensitive but least specific modality and should be used judiciously to avoid unnecessary biopsies. Dense breasts both increase cancer risk and decrease mammographic sensitivity, and supplemental screening should be discussed. A tissue marker clip should be placed at every biopsy site because it is essential for future surgical planning, especially if neoadjuvant chemotherapy is planned.

## References
- Siu AL, USPSTF. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):1599-1614.
- Monticciolo DL, et al. Breast cancer screening for average-risk women: Recommendations from the ACR Commission on Breast Imaging. J Am Coll Radiol. 2017;14(9):1137-1143.
- D'Orsi CJ, et al. ACR BI-RADS Atlas: Breast Imaging Reporting and Data System. 5th ed. American College of Radiology; 2013.
- Saslow D, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89.
- Bevers TB, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. 2024.